C R Bard Inc (N:BCR)

Business Focus: Medical Equipment, Supplies & Distribution

Recent Price for BCR
USD 334.500 +2.400 (+0.723%)
NYSE Delayed 15 minutes
Dec 15 Close
1-Day High 52-Week High P/E 1-Day Volume Mkt Cap ($Mil)
335.340 337.730 44.08 919,563 24,382.50
1-Day Low 52-Week Low Yield Avg. Volume  
332.305 216.545 0.3% 581,049  
Nov 29, 2017 07:50 ET
Market Trends Toward New Normal in Cloudera, C.R. Bard, Jabil Circuit, Valero Energy, Navient, and Interpace Diagnostics Group — Emerging Consolidated Expectations, Analyst Ratings
NEW YORK, Nov. 29, 2017 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Cloudera, Inc. (NYSE:CLDR), C.R. Bard, Inc. (NYSE:BCR), Jabil Circuit, Inc. (NYSE:JBL), Valero Energy Corporation (NYSE:VLO), Navient Corporation (NASDAQ:NAVI), and Interpace Diagnostics Group, Inc. (NASDAQ:IDXG), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.
Nov 16, 2017 06:36 ET
BD Statement On Merit Medical Agreement To Purchase BD, Bard Product Lines
FRANKLIN LAKES, N.J., Nov. 16, 2017 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, issued the following statement regarding today's announcement by Merit Medical Systems, Inc. that it has signed a definitive agreement to acquire BD's soft tissue core needle biopsy product line and C. R. Bard's (NYSE: BCR) Aspira® product line of tunneled home drainage catheters and accessories, contingent on the completion of the BD acquisition of Bard:...
Oct 25, 2017 20:15 ET
Bard Announces Third Quarter Results
C. R. Bard, Inc. (NYSE: BCR) today reported 2017 third quarter financial results. The company has included supplemental financial data on its website related to this earnings release. Third quarter 2017 net sales were $989.8 million, an increase of 5 percent over the prior-year period on an as-reported basis. Excluding the impact of foreign exchange, third quarter 2017 net sales also increased 5 percent over the prior-year period.
Oct 18, 2017 10:17 ET
BD Statement On European Commission Conditional Clearance Of Bard Acquisition
FRANKLIN LAKES, N.J., Oct. 18, 2017 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, issued the following statement regarding today's clearance by the European Commission for BD to acquire C.R. Bard (NYSE: BCR), contingent on BD divesting its soft tissue core needle biopsy product line:...
Oct 11, 2017 20:15 ET
Bard Declares Quarterly Dividend
The Board of Directors of C. R. Bard, Inc. (NYSE-BCR) today declared a regular quarterly dividend of 26 cents per share on Bard's common stock. In connection with the pending merger with Becton, Dickinson & Company, the quarterly dividend will be payable on December 29, 2017 to shareholders of record at the close of business on December 8, 2017.
Aug 08, 2017 16:54 ET
Bard Shareholders Approve Proposed Merger With Becton, Dickinson
MURRAY HILL, N.J. and FRANKLIN LAKES, N.J., Aug. 8, 2017 /PRNewswire/ -- C. R. Bard, Inc. (NYSE: BCR) ("Bard") and Becton, Dickinson and Company (NYSE: BDX) ("BD") today announced the results of Bard's special meeting of shareholders, held on August 8, 2017 and at which a quorum was present, for Bard shareholders to consider and vote upon the proposed merger of Bard with BD. Bard shareholders approved the definitive merger agreement, with approximately 99% of shares voting cast in favor of the proposal. ...
Jun 09, 2017 17:15 ET
BD and Bard Receive Second Requests from FTC under HSR Act
FRANKLIN LAKES, N.J., and MURRAY HILL, N.J., June 9, 2017 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and C. R. Bard, Inc. (NYSE: BCR), a medical technology leader in the fields of vascular, urology, oncology and surgical specialty products, announced today that the two companies have each received a request for additional information ("second request") from the Federal Trade Commission (FTC) in connection with BD's pending acquisition of Bard. The second request was issued under notification requirements of the Hart-Scott-Rodi...
Apr 27, 2017 16:39 ET
Apr 25, 2017 12:54 ET
WeissLaw LLP: The C. R. Bard, Inc. and Becton, Dickson and Company Merger May Not Be in the Best Interests of BCR Unitholders
NEW YORK, April 25, 2017 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of C. R. Bard, Inc. ("BCR" or the "Company")(NYSE: BCR) in connection with the proposed merger of the Company with Becton, Dickson and Company ("BDX")(NYSE: BDX).  Under the terms of the agreement, the Company's shareholders will receive $222.93 in cash and 0.5077 of a share of BDX for each share of BCR they own, representing consideration of $317.00 based on BDX's April 21 closing price.   ...
Apr 25, 2017 09:41 ET
C.R. BARD INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of C.R. Bard, Inc.
NEW ORLEANS, April 24, 2017 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of C.R. Bard, Inc. ("Bard" or the "Company") (NYSE: BCR) to Becton, Dickinson and Company (NYSE: BDX). Under the terms of the proposed transaction, shareholders of Bard will receive only $317.00 in cash for each share of Bard that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company....
Apr 24, 2017 16:07 ET
Harwood Feffer LLP Announces Investigation of C. R. Bard, Inc.
NEW YORK, April 24, 2017 /PRNewswire/ -- Harwood Feffer LLP (www.hfesq.com) is investigating potential claims against the board of directors of C. R. Bard, Inc. ("Bard" or the "Company") (NYSE: BCR) concerning the proposed acquisition of the Company by Becton, Dickinson and Company ("BD")....
Apr 23, 2017 21:23 ET
Act Now - Shareholder Alert: Monteverde & Associates PC Announces An Investigation Of C.R. Bard, Inc. - BCR
NEW YORK, April 23, 2017 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a boutique securities class action firm headquartered at the Empire State Building in New York City, is investigating  C.R. Bard, Inc. ("Bard" or the "Company") (NYSE: BCR) and its Board of Directors for potential breaches of fiduciary duties in connection with the sale of the Company to Becton, Dickinson and Company ("BD") (NYSE: BDX). The Company's stockholders will only receive $222.93 in cash and 0.5077 shares of BD stock for each Bard share they own. ...
Apr 23, 2017 17:05 ET
BD Announces Appointment Of Tom Polen As President
FRANKLIN LAKES, N.J., April 23, 2017 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today the appointment of Tom Polen, 43, as president of BD, effective immediately. In his new role, Mr. Polen will oversee all of BD's operating segments – the Medical and Life Sciences segments, as well as the new Interventional segment, which will include the C. R. Bard, Inc. (NYSE: BCR) businesses following the close of BD's acquisition of Bard, which was also announced today. Mr. Polen, currently executive vice president and president...
Apr 23, 2017 17:04 ET
BD To Acquire Bard For $24 Billion
FRANKLIN LAKES, N.J. and MURRAY HILL, N.J., April 23, 2017 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and C. R. Bard, Inc. (NYSE: BCR), a medical technology leader in the fields of vascular, urology, oncology and surgical specialty products, announced today a definitive agreement under which BD will acquire Bard for $317.00 per Bard common share in cash and stock, for a total consideration of $24 billion. The agreement has been unanimously approved by the Boards of Directors of both companies. ...